PSA and Prostate Cancer

Prostate cancer (PCa) is the most common non-cutaneous malignancy among men in the US. Discovery of prostate specific antigen (PSA) revolutionised screening of PCa. This book reviews the use of PSA as a biomarker and the various aspects of the possible role of PSA in prostate cancer. Prostate cancer (PCa) is a disease with high incidence and prevalence. It is the most common non-cutaneous malignancy among men in the U. S. Discovery of prostate specific antigen (PSA) revolutionised screening of PCa which was largely dependent on detection of prostatic and phosphatase and digital rectal examination. This book reviews the use of PSA as a biomarker and the various aspects of the possible role of PSA in prostate cancer. Moreover, the N-glycan structures described in PSA are examined from different origins, such as prostate tumour cell lines, seminal plasma from healthy donors, serum from PCa and prostate BPH patients. This book also sheds light on the potential clinical utility of cell-free DNA for prostate cancer screening, diagnosis and prognosis and assesses the attributes of circulating DNA in its environment. Recent advances and clinical trials in immunotherapy for prostate cancer are highlighted, along with an emphasis on those that employ prostate specific antigen (PSA) as a target. Other chapters evaluate post prostatectomy PSA level and its association with prostate cancer relapse. PSA and signal transduction in Prostate Cancer and PSA in bone metastases and its connection to the immune system are examined as well. Contents Preface Prostate Specific Antigen & Prostate Cancer PSA & Prostate Cancer Circulating Cell-Free Blood Nucleic Acids as a Potential Molecular Marker for Prostate Cancer Targeting Prostate Specific Antigen for the Treatment of Prostate Cancer Significance of PSA Glycosylation in Prostate Cancer Extending Ulam-Markov Indices from Mass-Spectra of Drugs & Proteins to Proteome Serum Profiles of Prostate Cancer Patients Molecular Mechanism of PSA Expression in Prostate Cancer Cells Prostate-Specific Antigen in Specific Immunotherapy for Prostate Cancer Feasibility & Usefulness of High-Dose-Rate Brachytherapy of Single Implant with Two Fractions Combined with External Beam Radiotherapy for Hormone-Naive Localized Prostate Cancer Screening for Prostate Cancer: Integrating the Current Evidence with Informed Decision Making Synthetic Peptides as Specific Activity Modulators of PSA Prostate Cancer Research in Thailand: A Summary Prostate Specific Antigen: A Note on Clinical Laboratory Medicine Aspect PSA Nadir Post-Radical Prostatectomy Might Predict Long-Term Biochemical Recurrence PSA & its Inference: A Note from Interferomics Approach Index.